NKTR: New rezpegaldesleukin data at EADV Congress 2026
Nkarta reported new rezpegaldesleukin data supporting long-term durability and disease improvement in patients with alopecia areata and atopic dermatitis at EADV Congress 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Nektar Therapeutics says rezpegaldesleukin shows early biomarker response in Phase 2b REZOLVE-AD
Nektar reported new biomarker results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis, presented at EADV Congress 2026, and said the results underpin a Phase 3 plan.
NKTR presents biomarker data on rezpegaldesleukin
New biomarker data were presented in a late-breaking oral presentation at EADV Congress 2026 showing early molecular responses to rezpegaldesleukin across multiple immune pathways dysregulated in atopic dermatitis.